Amphastar Pharmaceuticals appears dramatically undervalued when juxtaposed against its DCF Value of $90.97 and Graham Number of $25.91. The market’s current pricing suggests a significant mispricing, especially with a Forward P/E of 6.33 and an Earnings Yield of 9.20%, indicating robust earnings potential. The Altman Z-score of 2.18 suggests moderate financial health, but not without risk. This stock is a classic deep value play, with the market seemingly ignoring its intrinsic worth.
⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.